Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 1/20 | 0.51 |
| ▸ | MKNK1 | Q9BUB5 | 9/20 | 0.45 |
| ▸ | GRM4 | Q14833 | 6/20 | 0.45 |
| ▸ | DHFR | P00374 | 1/20 | 0.43 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.41 |
| ▸ | HTR2B | P41595 | 1/20 | 0.41 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5668065 | 0.88 | GRM4 (0.48) | GRM5MKNK1GRM4HTR2BMTNR1A | |
| SCHEMBL5667022 | 0.85 | GRM5 (0.68) | GRM5MKNK1GRM4DHFRHTR2B | |
| SCHEMBL8354922 | 0.84 | GRM5 (0.48) | GRM5MKNK1GRM4DHFRMKNK2 | |
| SCHEMBL5669963 | 0.84 | GRM5 (0.64) | GRM5MKNK1GRM4MKNK2PDE10A | |
| SCHEMBL181902 | 0.83 | MEN1 (0.56) | GRM5MKNK1GRM4MKNK2MEN1 | |
| SCHEMBL5216814 | 0.82 | GRM5 (0.45) | GRM5MKNK1GRM4MKNK2PDE10A | |
| SCHEMBL5221277 | 0.81 | GRM5 (0.46) | GRM5MKNK1GRM4MKNK2PDE10A | |
| SCHEMBL12410593 | 0.81 | CYP2A6 (0.47) | GRM5MKNK1GRM4MKNK2HTR2B | |
| SCHEMBL5216316 | 0.79 | MKNK1 (0.48) | GRM5MKNK1MKNK2KCNH2 | |
| SCHEMBL5667534 | 0.79 | GRM5 (0.71) | GRM5MKNK1GRM4DHFRHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060194807-A1 | Di-aryl substituted pyrazole modulators of metabotropic glutamate receptor-5 | MERCK & CO., INC. | 2006-08-31 | — | — | US | claimed |
| EP-1613614-A2 | DI-ARYL SUBSTITUTED PYRAZOLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 | Merck & Co., Inc. (US) | 2006-01-11 | — | — | EP | claimed |
| WO-2004089303-A2 | DI-ARYL SUBSTITUTED PYRAZOLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 | MERCK & CO., INC. (US) | 2004-10-21 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060194807-A1 | Di-aryl substituted pyrazole modulators of metabotropic glutamate receptor-5 | GRM5, GRM1, GRIK5 | GRM5 1/4885MKNK1 2084/4885GRM4 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.